Umesh Lalloo

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial”.

Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial

The Journal of Infectious Diseases(2020)10.1093/infdis/jiaa214

N/A

1.0DataRank · unranked

25 citations

Judith S. Currier, Amy Kantor, Laura Smeaton, Corinne Rivard, Jana Taron +17 more

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

Clinical Infectious Diseases(2022)10.1093/cid/ciac707

N/A

0.726DataRank · unranked

13 citations

Patrick Phillips, Ekaterina V. Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson +17 more

Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

PLoS ONE(2023)10.1371/journal.pone.0281580

N/A

0.403DataRank · unranked

6 citations

Lauren Komarow, Judith A. Aberg, David B. Clifford, Evelyn Hogg, Ashley McKhann +12 more

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine

Clinical Infectious Diseases(2021)10.1093/cid/ciab1037

N/A

0.365DataRank · unranked

5 citations

Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi +20 more

Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus–Tuberculosis Coinfection

Clinical Infectious Diseases(2021)10.1093/cid/ciab097

N/A

0DataRank · unranked

9 citations

Umesh Lalloo, Courtney V. Fletcher, Xingye Wu, Anthony T. Podany, Sandra Wagner Cardoso +3 more

Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings

Open Forum Infectious Diseases(2022)10.1093/ofid/ofac325

N/A

0DataRank · unranked

5 citations

Xin Sun, Sonya Krishnan, Mitch Matoga, Samuel Pierre, Katherine N. McIntire +17 more

Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102030

N/A

0DataRank · unranked

10 citations

Sonya Krishnan, Padmini Salgame, Yukari C. Manabe, Mina C. Hosseinipour, Gregory P. Bisson +18 more

1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis

Clinical Infectious Diseases(2023)10.1093/cid/ciad301

N/A

0DataRank · unranked

7 citations

Xingye Wu, Soyeon Kim, Katie McIntire, Linda Naini, Michael D. Hughes +21 more

A position statement and practical guide to the use of particulate filtering facepiece respirators (N95, FFP2, or equivalent) for South African health workers exposed to respiratory pathogens including Mycobacterium tuberculosis and SARS-CoV-2

African Journal of Thoracic and Critical Care Medicine(2021)10.7196/ajtccm.2021.v27i4.173

N/A

0DataRank · unranked

7 citations

Salome Charalambous, Aaron S Karat, A Von Delf, Umesh Lalloo, Richard N. van Zyl-Smit +26 more

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102787

N/A

0DataRank · unranked

3 citations

Carlee Moser, Nikolaus Jilg, Justin Ritz, David A. Wohl, Jonathan Z. Li +89 more

A position statement and practical guide to the use of particulate filtering facepiece (N95, FFP2, or equivalent) respirators for South African health care workers exposed to respiratory pathogens including M. tuberculosis and SARS-CoV-2

AfricArXiv (OSF Preprints)(2021)10.31730/osf.io/zp9wn

N/A

0DataRank · unranked

1 citations

Salome Charalambous, Aaron S Karat, Arne von Delft, Umesh Lalloo, Richard N. van Zyl-Smit +26 more